18251-1-AP
antibody from Proteintech Group
Targeting: PDCD1LG2
B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2
Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 18251-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- PD-L2/CD273 antibody
- Antibody type
- Polyclonal
- Description
- PD-L2/CD273 antibody (Cat. #18251-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.
ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
IFI30 expression is an independent unfavourable prognostic factor in glioma.
Programmed death-ligand 2 (PD-L2) expression in bladder cancer.
PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.
Jomrich G, Kollmann D, Wilfing L, Radosavljevic S, Ramazanova D, Ristl R, Grose RP, Ilhan-Mutlu A, Preusser M, Fassnacht C, Tsai YC, Guenova E, Schoppmann SF
European surgery : ACA : Acta chirurgica Austriaca 2021;53(6):287-293
European surgery : ACA : Acta chirurgica Austriaca 2021;53(6):287-293
ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.
Katsurahara K, Shiozaki A, Kosuga T, Shimizu H, Kudou M, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Konishi E, Otsuji E
Cancer science 2021 Mar;112(3):1026-1037
Cancer science 2021 Mar;112(3):1026-1037
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C, Zou Y
Cell death discovery 2021 Jun 5;7(1):136
Cell death discovery 2021 Jun 5;7(1):136
IFI30 expression is an independent unfavourable prognostic factor in glioma.
Liu X, Song C, Yang S, Ji Q, Chen F, Li W
Journal of cellular and molecular medicine 2020 Nov;24(21):12433-12443
Journal of cellular and molecular medicine 2020 Nov;24(21):12433-12443
Programmed death-ligand 2 (PD-L2) expression in bladder cancer.
Yang Y, Wang X, Bai Y, Feng D, Li A, Tang Y, Wei X, Han P
Urologic oncology 2020 Jun;38(6):603.e9-603.e15
Urologic oncology 2020 Jun;38(6):603.e9-603.e15
PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Wang ZL, Li GZ, Wang QW, Bao ZS, Wang Z, Zhang CB, Jiang T
Oncoimmunology 2019;8(2):e1541535
Oncoimmunology 2019;8(2):e1541535
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, Chaulagain A, Chen Y, Wang Y, Lin L, Yan B, Wang Y, Wang W, Zhao W, Zhong Z
Antiviral research 2019 Jun;166:1-10
Antiviral research 2019 Jun;166:1-10
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Mussetti A, Pellegrinelli A, Cieri N, Garzone G, Dominoni F, Cabras A, Montefusco V
Annals of hematology 2019 Jul;98(7):1713-1720
Annals of hematology 2019 Jul;98(7):1713-1720
Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.
Xu Q, Long Q, Zhu D, Fu D, Zhang B, Han L, Qian M, Guo J, Xu J, Cao L, Chin YE, Coppé JP, Lam EW, Campisi J, Sun Y
Aging cell 2019 Dec;18(6):e13027
Aging cell 2019 Dec;18(6):e13027
No comments: Submit comment
No validations: Submit validation data